christianfruiz.bsky.social
@christianfruiz.bsky.social
12 followers 30 following 3 posts
Posts Media Videos Starter Packs
christianfruiz.bsky.social
christianfruiz.bsky.social @christianfruiz.bsky.social · Jul 16
🎉 So proud of my wife
Natasha Pinto Medici on her latest co–first author paper in @ScienceTransMed!
🚀 Her team introduces TMAB3 — a tumor-targeted, RNA-binding antibody that delivers RNA directly into tumors after systemic injection.
www.science.org/doi/10.1126/...
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer
A cell-penetrating and RNA binding antibody forms noncovalent complexes with an immunogenic RNA to target tumors and achieve antitumor efficacy.
www.science.org
1 4
Reposted
muzumdarlab.bsky.social
Muzumdar Lab @muzumdarlab.bsky.social · Jul 15
Way to go, @xiangyuge.bsky.social, for a fantastic talk on how #PI3K governs resistance to #KRAS inhibition in #PancreaticCancer cells @faseborg.bsky.social Protein Phosphorylation! @yalepathology.bsky.social @yalecancer.bsky.social. Check out her preprint: www.biorxiv.org/content/10.1...
Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle....
www.biorxiv.org
2 5
christianfruiz.bsky.social
christianfruiz.bsky.social @christianfruiz.bsky.social · Jun 25
PI3K takes the spotlight when KRAS is inhibited in PDAC. Fantastic preprint from @xiangyuge.bsky.social now up!
muzumdarlab.bsky.social
Muzumdar Lab @muzumdarlab.bsky.social · Jun 25
1/🚨 New preprint out!🚨
We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance.
🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator.
📄 www.biorxiv.org/content/10.1...
Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle....
www.biorxiv.org
2
christianfruiz.bsky.social
christianfruiz.bsky.social @christianfruiz.bsky.social · Apr 7
🔁 Check out our new preprint exploring how dietary fats influence pancreatic cancer progression through ferroptosis sensitivity! 🦠🔥 In our model, MUFAs promote tumorigenesis, while PUFAs show protective effects. Read more here 📄👇 #CancerResearch #Ferroptosis #LipidMetabolism #bioRxiv”
muzumdarlab.bsky.social
Muzumdar Lab @muzumdarlab.bsky.social · Apr 7
9/ 💬 Excited to discuss! Questions, feedback, and collaborations welcome! 🤝 #CancerBiology #DietAndCancer #Ferroptosis #PancreaticCancer www.biorxiv.org/content/10.1...
Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive ...
www.biorxiv.org